We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KD:NYSEKyndryl Holdings, Inc. Analysis

Data as of 2026-06-02 - not real-time

$12.89

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is currently trading below its short‑term moving average and well beneath its longer‑term averages, indicating a bearish price environment. Momentum indicators show a neutral RSI and a MACD histogram that has turned positive, suggesting a modest bullish impulse amid overall weakness. Volume has been trending lower, reinforcing the lack of buying pressure. Recent earnings released a flat revenue year‑over‑year and a non‑GAAP profit that fell well short of consensus, highlighting earnings disappointment. The company’s margins remain thin, with operating profitability barely above break‑even.
Valuation metrics reveal a price‑to‑earnings multiple that is dramatically lower than the industry average, and a discounted cash‑flow model points to a substantial upside potential. The balance sheet shows ample cash relative to debt, yet the debt‑to‑equity ratio is extremely high, underscoring leverage concerns. Market sentiment is in the “extreme greed” zone, but the stock’s high thirty‑day volatility and beta above the market suggest heightened risk. Given the combination of undervaluation, weak earnings momentum, and elevated risk, investors should approach the position cautiously.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • recent earnings miss
  • price below short‑term average
  • decreasing trading volume

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • discounted cash‑flow upside
  • low price‑to‑earnings relative to peers
  • strong cash position despite leverage

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • strategic AI partnership and service diversification
  • steady demand for IT infrastructure services
  • persistent leverage and debt concerns

Key Metrics & Analysis

Financial Health

Revenue Growth-0.80%
Profit Margin1.31%
P/E Ratio15.2
ROE15.09%
ROA3.33%
Debt/Equity383.59
P/B Ratio2.4
Op. Cash Flow$948.0M
Free Cash Flow$2.8B
Industry P/E42.9

Technical Analysis

TrendBearish
RSI54.6
Support$10.88
Resistance$14.77
MA 20$12.25
MA 50$12.88
MA 200$21.93
MACDBullish
VolumeDecreasing
Fear & Greed Index92.77

Valuation

Fair Value$154.34
Target Price$14.10
Upside/Downside9.39%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.20
Volatility54.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.